161 related articles for article (PubMed ID: 35039206)
1. Efficacy of sunscreen with photolyase or regular sunscreen associated with topical antioxidants in treating advanced photodamage and cutaneous field cancerization: a randomized clinical trial.
Alvares BA; Miola AC; Schimitt JV; Miot HA; Abbade LPF
An Bras Dermatol; 2022; 97(2):157-165. PubMed ID: 35039206
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a photolyase-based device in the treatment of cancerization field in patients with actinic keratosis and non-melanoma skin cancer.
Puviani M; Barcella A; Milani M
G Ital Dermatol Venereol; 2013 Dec; 148(6):693-8. PubMed ID: 24442053
[TBL] [Abstract][Full Text] [Related]
3. The use of a sunscreen containing DNA-photolyase in the treatment of patients with field cancerization and multiple actinic keratoses: a case-series.
Navarrete-Dechent C; Molgó M
Dermatol Online J; 2017 Jan; 23(1):. PubMed ID: 28329483
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effects of Sunscreens Alone vs Sunscreens Plus DNA Repair Enzymes in Patients With Actinic Keratosis: Clinical and Molecular Findings from a 6-Month, Randomized, Clinical Study.
Carducci M; Pavone PS; De Marco G; Lovati S; Altabas V; Altabas K; Emanuele E
J Drugs Dermatol; 2015 Sep; 14(9):986-90. PubMed ID: 26355618
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of a film-forming medical device containing sunscreen (50+) and piroxicam 0.8% in actinic keratosis and field cancerization: a multicenter, assessor-blinded, 3 month trial.
Puviani M; Galloni C; Marchetti S; Sergio Pavone P; Lovati S; Pistone G; Caputo V; Tilotta G; Scarcella G; Campione E; Diluvio L; Garofalo V; Bianchi L; Milani M
Curr Med Res Opin; 2017 Jul; 33(7):1255-1259. PubMed ID: 28358282
[TBL] [Abstract][Full Text] [Related]
6. Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments).
Hasan ZU; Ahmed I; Matin RN; Homer V; Lear JT; Ismail F; Whitmarsh T; Green AC; Thomson J; Milligan A; Hogan S; Van-de-Velde V; Mitchell-Worsford L; Kentley J; Gaunt C; Jefferson-Hulme Y; Bowden SJ; Gaunt P; Wheatley K; Proby CM; Harwood CA
Br J Dermatol; 2022 Sep; 187(3):324-337. PubMed ID: 34988975
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of 0.5% colchicine cream versus 5% 5-fluorouracil cream in the treatment of cutaneous field cancerization: a randomized clinical trial.
Teixeira AS; Martins IMC; Miola AC; Miot HA
An Bras Dermatol; 2024 Apr; ():. PubMed ID: 38614940
[TBL] [Abstract][Full Text] [Related]
8. Effects of topical piroxicam and sun filters in actinic keratosis evolution and field cancerization: a two-center, assessor-blinded, clinical, confocal microscopy and dermoscopy evaluation trial.
Agozzino M; Russo T; Franceschini C; Mazzilli S; Garofalo V; Campione E; Bianchi L; Milani M; Argenziano G
Curr Med Res Opin; 2019 Oct; 35(10):1785-1792. PubMed ID: 31148490
[No Abstract] [Full Text] [Related]
9. Management of cancerization field with a medical device containing photolyase: a randomized, double-blind, parallel-group pilot study.
Moscarella E; Argenziano G; Longo C; Aladren S
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):e401-e403. PubMed ID: 28294419
[No Abstract] [Full Text] [Related]
10. Effectiveness and safety of 0·5% colchicine cream vs. photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratosis and skin field cancerization of the forearms: a randomized controlled trial.
Miola AC; Ferreira ER; Lima TRR; Schmitt JV; Abbade LPF; Miot HA
Br J Dermatol; 2018 Nov; 179(5):1081-1087. PubMed ID: 29862491
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of different photoprotection strategies in preventing actinic keratosis new lesions after photodynamic therapy. The ATHENA study: a two-center, randomized, prospective, assessor-blinded pragmatic trial.
Pavone PS; Lovati S; Scarcella G; Milani M
Curr Med Res Opin; 2019 Jan; 35(1):141-145. PubMed ID: 30404544
[No Abstract] [Full Text] [Related]
12. Evaluation of an SPF50 Sunscreen Containing Photolyase and Antioxidants for its Anti-Photoaging Properties and Photoprotection.
Kern J; Wood E; Almukhtar R; Angra K; Lipp M; Goldman M
J Drugs Dermatol; 2022 May; 21(5):517-520. PubMed ID: 35533024
[TBL] [Abstract][Full Text] [Related]
13. Randomized clinical trial testing the efficacy and safety of 0.5% colchicine cream versus photodynamic therapy with methyl aminolevulinate in the treatment of skin field cancerization: study protocol.
Miola AC; Ferreira ER; Abbade LPF; Schmitt JV; Miot HA
BMC Cancer; 2018 Mar; 18(1):340. PubMed ID: 29587662
[TBL] [Abstract][Full Text] [Related]
14. Long-term Efficacy of Topical Fluorouracil Cream, 5%, for Treating Actinic Keratosis: A Randomized Clinical Trial.
Pomerantz H; Hogan D; Eilers D; Swetter SM; Chen SC; Jacob SE; Warshaw EM; Stricklin G; Dellavalle RP; Sidhu-Malik N; Konnikov N; Werth VP; Keri J; Lew R; Weinstock MA;
JAMA Dermatol; 2015 Sep; 151(9):952-60. PubMed ID: 25950503
[TBL] [Abstract][Full Text] [Related]
15. Topical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): A randomized clinical trial.
Erlendsson AM; Karmisholt KE; Haak CS; Stender IM; Haedersdal M
J Am Acad Dermatol; 2016 Apr; 74(4):709-15. PubMed ID: 26810403
[TBL] [Abstract][Full Text] [Related]
16. Tretinoin (0.05% cream vs. 5% peel) for photoaging and field cancerization of the forearms: randomized, evaluator-blinded, clinical trial.
Sumita JM; Miot HA; Soares JLM; Raminelli ACP; Pereira SM; Ogawa MM; Picosse FR; Guadanhim LRS; Enokihara MMSS; Leonardi GR; Bagatin E
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1819-1826. PubMed ID: 29704456
[TBL] [Abstract][Full Text] [Related]
17. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3 multicenter, randomized, double-blind, placebo-controlled studies.
Swanson N; Smith CC; Kaur M; Goldenberg G
J Drugs Dermatol; 2013 Nov; 12(11):1278-82. PubMed ID: 24196337
[TBL] [Abstract][Full Text] [Related]
18. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Swanson N; Smith CC; Kaur M; Goldenberg G
J Drugs Dermatol; 2014 Feb; 13(2):166-9. PubMed ID: 24509967
[TBL] [Abstract][Full Text] [Related]
19. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial.
Gebauer K; Shumack S; Cowen PS
Br J Dermatol; 2009 Oct; 161(4):897-903. PubMed ID: 19545297
[TBL] [Abstract][Full Text] [Related]
20. Reproducibility and expression of skin biomarkers in sun-damaged skin and actinic keratoses.
Einspahr JG; Xu MJ; Warneke J; Saboda K; Ranger-Moore J; Bozzo P; Duckett L; Goldman R; Lin P; Buckmeier J; Alberts DS
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1841-8. PubMed ID: 17021352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
